findmyKOL

Christopher Bowlus, MD

Enriched profile

Chief, Division of Gastroenterology and Hepatology; Lena Valente Professor, Department of Internal Medicine, UC Davis School of Medicine · University of California, Davis

ORCIDNPI
Region🇺🇸 Sacramento, CA · West · United StatesSpecialtyGastroenterologyFocusLiver Diseases and Immunity+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2022–2025NIH funding1997–2015

Christopher Bowlus is Chief, Division of Gastroenterology and Hepatology; Lena Valente Professor, Department of Internal Medicine, UC Davis School of Medicine at University of California, Davis. OpenAlex indexes 434 publications with 17,169 citations (h-index 70); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Gastroenterology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Christopher Bowlus, MD, is Chief, Division of Gastroenterology and Hepatology at University of California, Davis, School of Medicine. The public record shows 434 publications with 17,169 citations (h-index 70), centered on Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment, Pediatric Hepatobiliary Diseases and Treatments. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 12 companies, 5 NIH-funded awards (1997–2015).

  • Most recent indexed publication: 2026 · The American journal of gastroenterology
  • Top research focus: Liver Diseases and Immunity
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 12 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Liver Cirrhosis, Biliary4 trialsCholangitis4 trialsCholangitis, Sclerosing3 trialsFatty Liver1 trial

Research focus

OpenAlex concept fingerprint
Liver Diseases and ImmunityLiver Disease Diagnosis and TreatmentPediatric Hepatobiliary Diseases and TreatmentsGallbladder and Bile Duct DisordersDrug Transport and Resistance Mechanisms

Drugs & molecules

across trials, industry payments and publications
Iqirvogeneric · ElafibranorClinical trialsIndustry payments10Publications1Livmarligeneric · MaralixibatClinical trialsIndustry payments3Publications2Ocalivageneric · Obeticholic acidClinical trialsIndustry payments1Publications4

Works with

trial sponsors and companies reporting payments
Gilead Sciences, Inc.Clinical trialsIndustry payments21Ipsen Biopharmaceuticals, IncClinical trialsIndustry payments14GlaxoSmithKline, LLC.Clinical trialsIndustry payments12

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
434publications

Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.

17,169citations

Total citations across indexed works.

70h-index

Hirsch index (OpenAlex). i10-index 186.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
12companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
5NIH grants · 1997–2015

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

12 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    55.9%
    Bile Acid30.1%
    Ursodiol100%
    Part D52 patients
    Rifamycin Antibacterial8.4%
    Xifaxan100%
    Part D<11 patients
  • Cardiovascular

    18.4%
    Aldosterone antagonist (MRA)5.8%
    Spironolactone100%
    Part D13 patients
    Beta blocker5.4%
    Carvedilol60%Propranolol Hcl41%
    Part D<11 patients
  • Cancer & immunology

    14.1%
    Purine Antimetabolite14.1%
    Azathioprine100%
    Part D23 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)17.2% facility · 82.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

5 NIH research awards on record, funded 19972015 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

1 congress contribution (2016) across AMCP per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/christopher-bowlus-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Christopher-Bowlus

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • LinkedIn

    linkedin.com/in/christopher-bowlus-45336870

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

Mentions by others

where others cite or feature them
  • Apple Podcasts

    podcasts.apple.com/ie/podcast/christopher-bowlus-md-addressing-challenges-in-management/id252080751

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com
  • Other

    aasld.org/the-liver-meeting/speakers/christopher-l-bowlus-49128

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aasld.org
  • Other

    hcplive.com/authors/christopher-bowlus-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chief

    Division of Gastroenterology and Hepatology, UC Davis School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu
  • Lena Valente Professor

    UC Davis Department of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu
  • Professor in Residence

    MED: Internal Medicine - Gastroenterology, UC Davis School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucdavis.edu
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.